D-1161-2022 Class II Terminated
FDA drug recall D-1161-2022 was initiated by PD-Rx Pharmaceuticals, Inc. on Jun 6, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 1441 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 6, 2022
- Initiation Date
- Jun 6, 2022
- Termination Date
- Jun 17, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1441 bottles
Product description
Losartan Potassium Tablets, USP 25 mg, 90 Tablets bottles, Rx Only Marketed and Packaged By: PD-Rx Pharmaceuticals, Inc. Oklahoma City, OK 73127 Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108 SIDCO Pharmaceutical Complex, Alathur, Kanchipuram-603 110, Tamilnadu, India NDC 72789-163-90 UPC 3 72789 16390 1
Reason for recall
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Distribution pattern
Nationwide
Code information
Lots: D21C18 Exp. 09/30/22; E21A28 Exp. 09/30/22; E21C04 Exp. 09/30/22; E21D59 Exp. 09/30/22; G21B65 Exp. 09/30/22; H21A12 Exp. 09/30/22; H21D42 Exp. 09/30/22; K21D19 Exp. 10/31/22; A22A73 Exp. 10/31/22
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1161-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026